INTERNATIONAL AIDS VACCINE INITIATIVE INC. - THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. THESE VACCINES ARE BASED ON RECOMBINANT EXPRESSION OF FILOVIRUS GLYCOPROTEINS IN

PIID: 75A50121C00077Solicitation ID: BAA18100SOL00003

Signed Date: Oct 29, 2025Effective Date: Sep 30, 2021End Date: Closes in 399 days

Award $

$95.6M

Vendor

INTERNATIONAL AIDS VACCINE INITIATIVE INC.

NAICS

541714

Signed Date

Oct 29, 2025

Key Details

Dollars Obligated

$95.6M

Base & All Options

Awarding Agency

Department of Health and Human Services

Awarding Sub-Agency

Office of Assistant Secretary for Preparedness and Response

NAICS Code

541714 - RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)

Product Service Code

AN42 - HEALTH R&D SERVICES; HEALTH CARE - OTHER; APPLIED RESEARCH

Extent Competed

FULL AND OPEN COMPETITION

Number of Offers

Place of Performance

NEW YORK, NY, 100042743, CD-NY-10

Description

THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. THESE VACCINES ARE BASED ON RECOMBINANT EXPRESSION OF FILOVIRUS GLYCOPROTEINS IN

Context & Analysis

On Oct 29, 2025, Department of Health and Human Services obligated $95,592,504 to INTERNATIONAL AIDS VACCINE INITIATIVE INC. for the overall objective of this contract is to advance the development of monovalent vaccines for prevention of marburg virus (marv) and sudan ebolavirus (sudv) disease. these vaccines are based on rec…. The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a firm fixed price contract. Competition extent: full and open competition with 1 offer received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in NEW YORK, NY. The contract is scheduled through Nov 30, 2027 — approximately 13 months remaining.

Market context

Recompete outlook: Ends Nov 30, 2027, in 13 months. Recompete signal as of Oct 27, 2026: 27/100, combining time to the end date, the incumbent's history with this agency, whether the award was competed, and its size.
Competition: Competed, with 1 offer. 96% of 222 awards in this market (Department of Health and Human Services awards in NAICS 541714 over the last 3 years) were competed; median 1 offers.
Award size: At $95.6M, this award is larger than three in four of the 212 priced Department of Health and Human Services awards in NAICS 541714 over the last 3 years (median $1.2M).
Incumbent at this agency: INTERNATIONAL AIDS VACCINE INITIATIVE INC. has 1 other award from Department of Health and Human Services, totalling $3.6M, in 2025.
Largest vendors in this market: By obligations, Department of Health and Human Services awards in NAICS 541714 over the last 3 years.
TECHNICAL RESOURCES INTERNATIONAL, INC. — 4 awards, $379.6M
ALLUCENT GOVERNMENT SERVICES (US) LLC — 2 awards, $373.2M
ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC. — 4 awards, $342.2M
PARATEK PHARMACEUTICALS, INC — 1 award, $265.3M
GENENTECH INC — 1 award, $243.7M